Gastroenterology Flashcards
Treatment of Barrett’s with a reduction in adenocarcinoma
High dose PPI and aspirin
Barrett’s surveillance
No dysplasia - surveillance
Low grade at 2 endos 6 months apart- RFA
High grade dysplasia - oesophagectomy vs low endo resection followed by RFA
Post RFA - 5 years
Portal HTN pressure
> 5mmHg
Primary prophylaxis if nil bleed
Non selective b blocker or ligation
Prevention of hepatorenal syndrome in SBP
IV albumen at diagnosis and day 3
High ALP and GGT and antimitochondrial antibodies
PBC
PBC treatment
Ursodeoxycholic acid
Liver transplant referral
Kings college criteria (not paracetamol)
PT >100 OR 3 of
Age over 40
Jaundice for 7 days
PT over 50
Bili over 180
Non A or Non B hepatitis, Wilson’s or drugs
Type 1 AIH
Anti Smooth muscle antibodies and ANA
Type 2 AIH
Anti LKM1
Target antigen: Cyp450 2D6
Haemachromatosis gene mutation
HFE gene mutation (C282Y or H63D)
Test for Pancreatic insufficiency with chronic pancreatitis
Faecal elastase
FAP gene
APC gene chromosome 5
Tumour suppressor gene
Autosomal dominant
MYH associated polyposis
MutY gene
HNPCC gene mutations
MSH2 (60%) and MLH1 (30%)
Mismatch repair genes causing micro satellite instability
Right sided tumour
> 10 adenomas
3 cases, 2 generations, 1 age <50
5-AZA SE
Hepatotoxicity Myelosuppressions Allergy/pancreatitis NHL Non melanomatous skin cancer
No effect in pregnancy
Risk of progression from high grade dysplasia to adenocarcinoma
10%
The benefit of IV PPI pre endoscopy
Reduces endoscopy therapy does not reduce mortality, rebleed or death
Treatment of acute bleeding UGIB
Adrenaline + diathermy/clip has mortality/rebleed benefit
Post endoscopy PPI IV for 72 hours (oral similarly efficacious)
Restart aspirin at 3 days
Restart warfarin/DOAC 2 weeks
High gradient ascites
Serum albumin: ascites alumen >11g/L
Portal HTN